Optimi Health Corp. — News

/PRNewswire/ - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of

prnewswire.com - 2026-06-29 11:13:00

Optimi's 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression. The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in September 2025.

globenewswire.com - 2026-06-29 09:00:00

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin finished drug products, formulated at 1 mg and 2 mg dosages. The products are available to qualified, authorized clinical research organizations.

globenewswire.com - 2026-06-16 08:30:00

/PRNewswire/ - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of

prnewswire.com - 2026-06-10 14:24:00

The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from Health Canada and import authorization from the UK Home Office The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from Health Canada and import authorization from the UK Home Office

globenewswire.com - 2026-06-10 09:15:00

Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development PR Newswire VANCOUVER, BC,

gurufocus.com - 2026-06-08 13:00:00

/PRNewswire/ - via IBN - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer

prnewswire.com - 2026-06-08 12:54:00

Recent US executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review and expanded patient access Ibogaine is under investigation to treat PTSD, opioid use disorder and traumatic brain injury VANCOUVER, British Columbia, June 08, 2026 (GLOBE NEWSWIRE) -- via IBN – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today provided an update on its recently announced Ibogaine Initiative . Optimi has secured naturally derived ibogaine from two sources, in both hydrochloride (HCl) and freebase form.

globenewswire.com - 2026-06-08 08:00:00

Optimi's 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United States and Europe

globenewswire.com - 2026-06-02 07:30:00

Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia

gurufocus.com - 2026-05-29 12:00:00

Updated TGA recommendations broaden therapist eligibility, accept a wider range of treatment settings, and reinforce Australia's position as the world's leading commercial market for prescribed psilocybin and MDMA VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- via IBN – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage psychedelic pharmaceutical manufacturer, today acknowledged the final recommendations published by the Therapeutic Goods Administration ("TGA") following its targeted consultation on the Authorized Prescriber ("AP") scheme for psilocybin and MDMA. Under the AP scheme, authorized psychiatrists may prescribe Optimi's MDMA for the treatment of post-traumatic stress disorder ("PTSD") and psilocybin for treatment-resistant depression ("TRD") from the Company's GMP-compliant production facility in Canada, making Australia the first country in the world to recognize, and regulate, both substances as medicines for these indications.

globenewswire.com - 2026-05-29 08:30:00

New York, May 27, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research LLC, an equity research firm with a focus on small capitalization public companies has initiated coverage of Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN). The research summary below is from a report commissioned by Optimi Health Corp. and produced by Diamond Equity Research.The in-depth 40-page initiation report includes detailed information on Optimi Health's business model, services, industry overview, financials, management profile, and risks.

globenewswire.com - 2026-05-27 08:00:00

The 6% naturally derived extract is set to be encapsulated for use in patients suffering from treatment-resistant depression under Australia's Authorised Prescriber Scheme, where no serious adverse events have been reported as of December 2025 Vancouver, British Columbia--(Newsfile Corp. - May 26, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of a production run of naturally derived psilocybin extract measuring approximately 6% psilocybin content, representing the highest-purity botanical psilocybin extract produced by the Company to date. The milestone reflects sustained gains across Optimi's cultivation program.

newsfilecorp.com - 2026-05-26 07:00:00

Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today closed its previously announced underwritten public offering (the "Offering") in connection with the uplisting of its common shares to the Nasdaq Capital Market. The Company issued 2,400,000 common shares at a price of US$6.25 per share.

newsfilecorp.com - 2026-05-21 13:07:00

NORTH PALM BEACH, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") and EMJ Crypto Technologies ("EMJX"), a digital-asset treasury operating platform with which the Company has entered into a definitive merger agreement, today announced investing in Optimi Health Corp. (NASDAQ: OPTH), a commercial-stage pharmaceutical company focused on manufacturing and distribution of GMP-grade psychedelic drug products for mental health therapies including Psilocybin.

globenewswire.com - 2026-05-21 09:00:00

/PRNewswire/ - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on

prnewswire.com - 2026-05-20 11:30:00

Common Shares to Trade on the Nasdaq Capital Market Under the Symbol "OPTH" Vancouver, British Columbia--(Newsfile Corp. - May 20, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced the pricing of its underwritten public offering (the " Offering") in connection with the uplisting of its common shares to the Nasdaq Capital Market. The Company is offering 2,400,000 common shares at a public offering price of US$6.25 per share.

newsfilecorp.com - 2026-05-20 08:00:00

Vancouver, British Columbia--(Newsfile Corp. - April 23, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that further to its press release dated March 16, 2026, it intends to complete a portion of its previously announced offering of common shares (the "Offering") in Canada pursuant to the Listed Issuer Financing Exemption contained in Part A of National Instrument 45-106 - Prospectus Exemptions, as modified by Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the "Listed Issuer Financing Exemption"). The offering price and certain terms of the securities to be offered will be determined in the context of the market at the time of pricing.

newsfilecorp.com - 2026-04-23 07:00:00